Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MRI equipment use "must cease" in the EU - unless derogation possible under forthcoming law

This article was originally published in Clinica

Executive Summary

"I do not see how the Commission can address the threat to the future of MRI without proposing an EU-wide derogation for MRI from the scope of the [Physical Agents] Directive on public health grounds." That is the view of Professor Gabriel Krestin, professor and chairman of the Department of Radiology at Erasmus University in response to the publication of a new study by Professor Stuart Crozier, professor and director of the biomedical engineering group at the University of Queensland. Prof Crozier's report, published on June 14, demonstrates that changes to existing MRI practice would not be sufficient to comply with Directive 2004/40/EC, the EU Physical Agents Directive, which is due to be fully enforced in April 2008; thus, the use of current MRI equipment and procedures would need to stop.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel